Core Insights - BriaCell Therapeutics Corp. announced a significant clinical response in a metastatic breast cancer patient treated with Bria-OTS™, including complete resolution of lung metastasis after four injection cycles [1][5][7] - Bria-OTS™ is a personalized off-the-shelf immunotherapy currently in a Phase 1/2a dose escalation study for metastatic recurrent breast cancer, representing an advancement over BriaCell's previous candidate, Bria-IMT™ [2][6] - The initial patient in the study, a 78-year-old woman, had extensive metastases and showed stable disease elsewhere after treatment, indicating the potential effectiveness of Bria-OTS™ [5][6] Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [8] - The company is exploring the therapeutic potential of Bria-OTS™ not only in metastatic breast cancer but also plans to extend its application to prostate cancer, melanoma, and lung cancer [6][8] Clinical Study Details - The Phase 1/2a clinical trial is designed to evaluate the safety and efficacy of Bria-OTS™ as a monotherapy initially, followed by combination therapy with an immune checkpoint inhibitor [6][7] - Key inclusion criteria for the study include recurrent metastatic breast cancer and at least two prior failed systemic therapy attempts [6]
BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™